[1]谷军保,鲍学斌,马　钊.XB130在胃癌组织中的表达及临床意义[J].新乡医学院学报,2018,35(1):061-64.[doi:10.7683/xxyxyxb.2018.01.015]
　GU Jun-bao,BAO Xue-bin,MA Zhao.The clinical significance of the expression of XB130 in gastric cancer tissues[J].Journal of Xinxiang Medical University,2018,35(1):061-64.[doi:10.7683/xxyxyxb.2018.01.015]
点击复制

XB130在胃癌组织中的表达及临床意义
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
35
期数:
2018年1
页码:
061-64
栏目:
临床研究
出版日期:
2018-01-05

文章信息/Info

Title:
The clinical significance of the expression of XB130 in gastric cancer tissues
作者:
谷军保; 鲍学斌; 马　钊
（河南省人民医院胃肠外科，河南　郑州　450003）
Author(s):
GU Jun-bao; BAO Xue-bin; MA Zhao
（Department of Gastrointestinal Surgery，Henan Provincial People′s Hospital，Zhengzhou 450003，Henan Province，China）
关键词:
胃癌; XB130; 免疫组织化学; 聚合酶链反应
Keywords:
gastric cancer; XB130; immunohistochemistry; polymerase chain reaction
分类号:
R735.2
DOI:
10.7683/xxyxyxb.2018.01.015
文献标志码:
A
摘要:
目的　探讨XB130在胃癌组织中的表达及其与胃癌分化程度、淋巴结转移及患者生存期的关系。方法　收集2011年6月至2012年6月河南省人民医院保存的胃癌组织标本及相应的癌旁组织标本各72例，采用免疫组织化学法检测胃癌及癌旁组织中XB130蛋白表达，采用实时定量荧光聚合酶链反应检测胃癌及癌旁组织中XB130 mRNA表达，并分析XB130表达与胃癌临床病理特征的关系。结果　72例胃癌组织标本中，XB130蛋白阳性表达26例，阴性表达46例，阳性表达率36.1%（26/72）；72例癌旁组织标本中，XB130蛋白阳性表达52例，阴性表达20例，阳性表达率72.2%（52/72）；胃癌组织中XB130蛋白阳性表达率显著低于癌旁组织（χ2=16.200，P<0.05）。低、中分化胃癌组织中XB130蛋白阳性表达率显著低于高分化胃癌组织（χ2=5.786，P<0.05），有淋巴结转移者胃癌组织中XB130蛋白阳性表达率显著低于无淋巴结转移者（χ2=4.281，P<0.05）。胃癌组织和癌旁组织中XB130 mRNA相对表达量分别为1.52±0.46、3.28±0.51，胃癌组织中XB130 mRNA表达显著低于癌旁组织（t=-21.744，P<0.05）。高分化胃癌组织中XB130 mRNA表达显著高于低、中分化胃癌组织（t=-13.982，P<0.05），有淋巴结转移者胃癌组织中XB130 mRNA表达显著低于无淋巴结转移者（t=-19.906，P<0.05）。XB130 mRNA高表达与低表达患者的平均生存期分别为（37.040±14.826）、（21.529±11.789）个月，XB130 mRNA高表达胃癌患者的生存期显著长于XB130低表达患者（t=9.121，P<0.05）。结论　XB130可能参与了胃癌的发生和发展，且与胃癌分化程度、淋巴结转移及患者生存期有关。
Abstract:
Objective　To investigate the relationship between the expression of XB130 and the histodifferentiation，lymph node metastasis and survival time of patients with gastric cancer.Methods　Seventy-two specimens of gastric cancer tissues and seventy-two specimens of paracancerous tissues were collected from June 2011 to June 2012 in Henan Province People′s Hospital.The expression of XB130 protein in gastric cancer and paracancerous tissues was detected by immunohistochemistry.The expression of XB130 mRNA in gastric cancer and paracancerous tissues was detected by real-time quantitative polymerase chain reaction.The relationship between the expression of XB130 and clinicopathological features of gastric cancer was analyzed.Results　There were 26 cases of positive expression of XB130 protein and 46 cases of negative expression of XB130 protein among the 72 cases of gastric cancer tissues，and the positive expression rate was 36.1% （26/72）.There were 52 cases of positive expression of XB130 protein and 20 cases of negative expression of XB130 protein among the 72 cases of paracancerous tissues，and the positive expression rate was 72.2% （52/72）.The positive expression rate of XB130 protein in gastric cancer tissues was significantly lower than that in paracancerous tissues （χ2=16.200，P<0.05）.The positive expression rate of XB130 protein in poorly and moderately differentiated gastric cancer tissues was significantly lower than that in well differentiated gastric cancer tissues （χ2=5.786，P<0.05）.The positive expression rate of XB130 protein in gastric cancer tissues with lymph node metastasis was significantly lower than that in gastric cancer tissues without lymph node metastasis （χ2=4.281，P<0.05）.The relative expression of XB130 mRNA in gastric cancer tissues and paracancerous tissues was 1.52±0.46 and 2.28±0.51 respectively，the expression of XB130 mRNA in gastric cancer tissues was significantly lower than that in paracancerous tissues （t=-21.744，P<0.05）.The expression of XB130 mRNA in well differentiated gastric cancer tissues was significantly higher than that in poorly and moderately differentiated gastric cancer tissues （t=-13.982，P<0.05）.The expression of XB130 mRNA in gastric cancer tissues with lymph node metastasis was significantly lower than that in gastric cancer tissues without lymph node metastasis （t=-19.906，P<0.05）.The mean survival time in patients with high and low expression of XB130 mRNA was （37.040±14.826） and （21.529±11.789） months respectively，the survival time in patients with high expression of XB130 mRNA was significantly higher than that in patients with low expression of XB130 mRNA （t=9.121，P<0.05）.Conclusion　XB130 may be involved in the occurrence and development of gastric cancer，and it is associated with the differentiation，lymph node metastasis and survival time of patients with gastric cancer.

参考文献/References:

［1］　KUROKAWA Y，YANG H K，CHO H，et al.Phase Ⅱ study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach［J］.Br J Cancer，2017，117（1）：25-32.
［2］　SHIOZAKI A，LODYGA M，BAI X H，et al.XB130，a novel adaptor protein，promotes thyroid tumor growth［J］.Am J Pathol，2011，178（1）：391-401.
［3］　XU J，BAI X H，LODYGA M，et al.XB130，a novel adaptor protein for signal transduction［J］.J Biol Chem，2007，282（22）：16401-16412.
［4］　LODYGA M，BAI X H，KAPUS A，et al.Adaptor protein XB130 is a Rac-controlled component of lamellipodia that regulates cell motility and invasion［J］.J Cell Sci，2010，123（Pt 23）：4156-4169.
［5］　LODYGA M，DE FALCO V，BAI X H，et al.XB130，a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI3-kinase pathway［J］.Oncogene，2009，28（7）：937-949.
［6］　BORDA F，MIRANDA C，BORDA A，et al.Relation between preoperative prognostic onodera′s index and postsurgery complications in the R0 gastric carcinoma resection［J］.An Sist Sanit Navar，2017，40（1）：67-75.
［7］　SZKARADKIEWICZ A，KARPINSKI T M，MAJEWSKI J，et al.The participation of p53 and bcl-2 proteins in gastric carcinomas associated with helicobacterpylori and/or epstein-barr virus （EBV）［J］.Pol J Microbiol，2015，64（3）：211-216.
［8］　OKUMURA T，ERICKSEN R E，TAKAISHI S，et al.K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation，an altered microenvironment，and progression to intraepithelial neoplasia［J］.Cancer Res，2010，70（21）：8435-8445.
［9］　VAN AALST S，LUDWIG I S，VAN KOOTEN P J，et al.Dynamics of APC recruitment at the site of injection following injection of vaccine adjuvants［J］.Vaccine，2017，35（12）：1622-1629.
［10］　LI X，ZHENG X，XU B，et al.Lower Bmi-1 expression may predict longer survival of colon cancer patients［J］.Cell Physiol Biochem，2016，39（6）：2421-2426.
［11］　LIU X，CAI H，HUANG H，et al.The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients［J］.PLoS One，2011，6（12）：e29670.
［12］　ZHANG J，CHEN Y H，LU Q.Pro-oncogenic and anti-oncogenic pathways：opportunities and challenges of cancer therapy［J］.Future Oncol，2010，6（4）：587-603.
［13］　DAMM K.ErbA：tumor suppressor turned oncogene［J］.FASEB J，1993，7（10）：904-909.
［14］　JOHNSON D G.The paradox of E2F1：oncogene and tumor suppressor gene［J］.Mol Carcinog，2000，27（3）：151-157.
［15］　SHI M，HUANG W，LIN L，et al.Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer［J］.PLoS One，2012，7（8）：e41660.
［16］　LIU X，WANG S，XIA X，et al.Synergistic role between p53 and JWA：prognostic and predictive biomarkers in gastric cancer［J］.PLoS One，2012，7（12）：e52348.

相似文献/References:

[1]陈赜,陈杰,严想元,等.腹腔镜辅助胃癌根治术治疗早期胃癌疗效观察[J].新乡医学院学报,,():000.
[2]于成功,萧树东,赵宪邨,等.胃癌胃良性病变患者血清和局部组织中IL—I水平及意义[J].新乡医学院学报,1996,13(03):220.
[3]王淑秀,赵卫星,和瑞芝,等.P~(53)和rasP~(21)在胃癌中表达的免疫组化研究[J].新乡医学院学报,1997,14(02):137.
[4]赵卫星,王淑秀,卢朝晖,等.幽门螺杆菌与胃癌基因抑癌基因突变的关系[J].新乡医学院学报,1997,14(03):203.
[5]王淑秀.抑癌基因和癌基因与胃癌[J].新乡医学院学报,1997,14(01):083.
[6]冯艳玲,乐晓萍,蔡新华.胃癌患者P16和P53蛋白的表达及其相互关系[J].新乡医学院学报,2000,17(06):403.
[7]周玲生.纤维胃镜粘膜活检1356 例病理分析[J].新乡医学院学报,2000,17(06):462.
[8]任金萍,王淑秀,付华民,等.青年与老年人胃癌中PCNA和AgNOR计数表达的对比研究[J].新乡医学院学报,2000,17(03):156.
[9]贾文英,张合喜,马彦民.幽门螺杆菌感染与胃癌关系的Meta 分析[J].新乡医学院学报,2000,17(05):328.
[10]窦天伟,刘 炯,罗志勇,等.复发胃癌再次手术42例疗效和随访结果[J].新乡医学院学报,2003,20(05):337.

更新日期/Last Update: 2018-01-05